Intranasal MEAI Shows 97% Permeation, Boosting Clearmind's Addiction Drug Prospects
CMND sits 23% above its 52-week low of $1.43.
Summary
Clearmind's intranasal MEAI formulation achieved 97.35% cumulative permeation at 180 minutes, comparable to a conventional solution, while extending nasal residence time. This addresses a key delivery challenge for its lead candidate targeting alcohol use disorder and obesity. The data builds on prior mucoadhesion results and supports advancement toward clinical trials. With a market cap under $3M and recent dilutive financings, positive preclinical data is critical to maintaining development momentum. The company recently completed Part A of its Phase I/II trial for oral CMND-100, and these intranasal results could open a differentiated delivery path.
At the time of this announcement, CMND was trading at $1.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $1.43 to $524.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.